Anocca AB raised $46 million to fund a phase I trial testing its CRISPR-edited T-cell receptor therapy targeting KRAS mutations in pancreatic cancer. Skyhawk Therapeutics secured a $2 billion collaboration with Merck KGaA to develop small-molecule RNA-targeted drugs for neurology and oncology indications, expanding their RNA medicine platform. These efforts reflect growing momentum in precision immunotherapy and gene editing for hard-to-treat cancers.